دورية أكاديمية
Antimicrobial Therapy Duration for Bloodstream Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex : A Retrospective Cohort Study.
العنوان: | Antimicrobial Therapy Duration for Bloodstream Infections Caused by Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex : A Retrospective Cohort Study. |
---|---|
المؤلفون: | Rodrigues RD; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil., Garcia RCL; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil., Bittencourt GA; Medical School, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, Brazil., Waichel VB; Medical School, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre 90619-900, Brazil., Garcia ECL; Medical School, Pontifícia Universidade Católica do Paraná, Curitiba 80215-901, Brazil., Rigatto MH; Medical Sciences Post Graduation Program, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil.; Medical School, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, Brazil.; Infectious Disease Service, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil. |
المصدر: | Antibiotics (Basel, Switzerland) [Antibiotics (Basel)] 2023 Mar 08; Vol. 12 (3). Date of Electronic Publication: 2023 Mar 08. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101637404 Publication Model: Electronic Cited Medium: Print ISSN: 2079-6382 (Print) Linking ISSN: 20796382 NLM ISO Abbreviation: Antibiotics (Basel) Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI AG, 2012- |
مستخلص: | Background: Ideal therapy duration for Pseudomonas aeruginosa or Acinetobacter baumannii-calcoaceticus complex (ABC) bloodstream infections (BSI) is not defined, especially in the context of carbapenem resistance. In this study, we compared short- (≤7 days) and long-term (>7 days) antimicrobial therapy duration for these infections. Methods: We performed a retrospective cohort study in two tertiary-care hospitals in Porto Alegre, Brazil, from 2013 to 2019. Eligible patients aged ≥18 years were included and excluded for the following criteria: polymicrobial infections, treatment with non-susceptible antibiotics, complicated infections, or early mortality (<8 days of active antimicrobial therapy). The 30-day mortality risk was evaluated using a Cox regression model. Results: We included 237 BSI episodes, 51.5% caused by ABC and 48.5% by Pseudomonas aeruginosa . Short-term therapy was not associated with 30-day mortality, adjusted hazard ratio 1.01, 95% confidence interval 0.47-2.20, p = 0.98, when adjusted for Pitt score ( p = 0.02), Charlson Comorbidity Index score ( p < 0.01), and carbapenem resistance ( p < 0.01). Among patients who survived, short-term therapy was associated with shorter hospital stay ( p < 0.01). Results were maintained in the subgroups of BSI caused by carbapenem-resistant bacteria ( p = 0.76), ABC ( p = 0.61), and Pseudomonas aeruginosa ( p = 0.39). Conclusions: Long-term therapies for non-complicated Pseudomonas aeruginosa and ABC BSI were not superior to short-term therapy for 30-day mortality. |
References: | Infect Dis Ther. 2022 Aug;11(4):1505-1519. (PMID: 35612693) J Chronic Dis. 1987;40(5):373-83. (PMID: 3558716) Clin Microbiol Infect. 2022 Apr;28(4):550-557. (PMID: 34508886) Antibiotics (Basel). 2021 Apr 22;10(5):. (PMID: 33922151) Expert Rev Anti Infect Ther. 2010 Jan;8(1):71-93. (PMID: 20014903) Clin Microbiol Rev. 2021 Mar 10;34(2):. (PMID: 33692149) J Antimicrob Chemother. 2021 Dec 24;77(1):223-228. (PMID: 34590681) Clin Infect Dis. 2019 Nov 13;69(11):2011-2014. (PMID: 30882137) Clin Microbiol Infect. 2023 Feb;29(2):165-170. (PMID: 36108947) Clin Infect Dis. 2020 Dec 23;71(Suppl 4):S386-S393. (PMID: 33367574) Curr Opin Infect Dis. 2021 Dec 1;34(6):681-685. (PMID: 34261908) BMC Infect Dis. 2022 Apr 5;22(1):336. (PMID: 35382769) Antimicrob Agents Chemother. 2019 Jun 24;63(7):. (PMID: 31010862) BMC Infect Dis. 2021 Jul 2;21(1):636. (PMID: 34215207) Clin Microbiol Infect. 2020 Feb;26(2):158-167. (PMID: 31733377) Sci Rep. 2022 May 20;12(1):8527. (PMID: 35595789) Open Forum Infect Dis. 2021 Oct 11;8(10):ofab434. (PMID: 34738022) Shock. 2009 Feb;31(2):146-50. (PMID: 18636041) Clin Infect Dis. 2009 Jul 1;49(1):1-45. (PMID: 19489710) J Med Microbiol. 2023 Feb;72(2):. (PMID: 36753436) Clin Infect Dis. 2019 Sep 13;69(7):1091-1098. (PMID: 30535100) Clin Infect Dis. 2021 Apr 8;72(7):1109-1116. (PMID: 33830222) |
معلومات مُعتمدة: | 2019-0740 Research Incentive Fund of the Hospital de Clínicas de Porto Alegre.; finance code 001 Coordenação de Aperfeiçoamento de Pessoal de Nível Superior-Brasil (CAPES) |
فهرسة مساهمة: | Keywords: Acinetobacter baumannii-calcoaceticus complex; Pseudomonas aeruginosa; bloodstream infections; treatment duration |
تواريخ الأحداث: | Date Created: 20230329 Latest Revision: 20230331 |
رمز التحديث: | 20230331 |
مُعرف محوري في PubMed: | PMC10044637 |
DOI: | 10.3390/antibiotics12030538 |
PMID: | 36978405 |
قاعدة البيانات: | MEDLINE |
تدمد: | 2079-6382 |
---|---|
DOI: | 10.3390/antibiotics12030538 |